Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 17-85 Jusohonmachi, 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan.
J Med Chem. 2011 May 12;54(9):3436-44. doi: 10.1021/jm200221q. Epub 2011 Apr 7.
A novel series of 1,6-dihydro-2H-indeno[5,4-b]furan derivatives were designed and synthesized as MT(2)-selective ligands. This scaffold was identified as a potent mimic of the 5-methoxy indole core of melatonin, and introduction of a cyclohexylmethyl group at the 7-position of this scaffold afforded an MT(2)-selective ligand 15 (K(i) = 0.012 nM) with high MT(1)/MT(2) selectivity (799). Compound 15 was identified as a potent full agonist for the MT(2) subtype and exhibited reentrainment effects to a new light/dark cycle in ICR mice at 3-30 mg/kg. This result demonstrated the involvement of the MT(2) receptors in chronobiotic activity.
设计并合成了一系列新型的 1,6-二氢-2H-茚并[5,4-b]呋喃衍生物作为 MT(2)-选择性配体。该支架被鉴定为褪黑素 5-甲氧基吲哚核心的有效模拟物,并且在该支架的 7-位引入环己基甲基基团提供了具有高 MT(1)/MT(2)选择性(799)的 MT(2)-选择性配体 15(K(i) = 0.012 nM)。化合物 15 被鉴定为 MT(2)亚型的有效完全激动剂,并在 3-30 mg/kg 剂量下在 ICR 小鼠中表现出对新的明暗周期的重新同步作用。该结果表明 MT(2)受体参与了生物钟活性。